A new drug that inhibits infant seizures in placental mammal models might open up new avenues for the treatment of brain disease in human newborns. Researchers have known that gluconate a little compound found in fruit associated honey acts as a medicine, inhibiting seizures by targeting the activity of channels that manage the flow of chloride ions in and out of infant neurons.
Over the past decades, many drugs have been developed to treat epilepsy in adults. However, neonatal epilepsy patients are often resistant to or do not respond to current anti-epilepsy drugs, and long-term use of some of these treatments may have side effects on brain development.
Gluconate can inhibit seizure activity in neonatal neurons. More importantly, gluconate suppresses seizure activity in neonatal animals more effectively than in adults.
Gluconate is already widely used in the food and pharmaceutical industries as an inactive food or drug additive. For example, it can bind with metal ions to form stable gluconate salts, such as calcium-gluconate, potassium-gluconate, and zinc-gluconate, that are used for the uptake of metal-ion supplements.
The research team found that gluconate inhibits neonatal seizures by targeting what are known as CLC-3 chloride channels. These channels mediate a large ion current in neonatal brains but are less active in adult brains. Gluconate appears to be too large to pass through the small openings of the CLC-3 channels and therefore acts as a channel blocker.
Get on a platform wherein you can get to know all about recent Pharmaceutical research by joining "3rd European Congress on Pharma and Pharmaceutical Sciences" scheduled to be held on July 24-25, 2019 at Rome, Italy.
To reserve your slot please follow: http://bit.ly/2TEeLfX
Mail us at europharma@pulsusglobal.com
Over the past decades, many drugs have been developed to treat epilepsy in adults. However, neonatal epilepsy patients are often resistant to or do not respond to current anti-epilepsy drugs, and long-term use of some of these treatments may have side effects on brain development.
Gluconate can inhibit seizure activity in neonatal neurons. More importantly, gluconate suppresses seizure activity in neonatal animals more effectively than in adults.
The research team found that gluconate inhibits neonatal seizures by targeting what are known as CLC-3 chloride channels. These channels mediate a large ion current in neonatal brains but are less active in adult brains. Gluconate appears to be too large to pass through the small openings of the CLC-3 channels and therefore acts as a channel blocker.
Get on a platform wherein you can get to know all about recent Pharmaceutical research by joining "3rd European Congress on Pharma and Pharmaceutical Sciences" scheduled to be held on July 24-25, 2019 at Rome, Italy.
To reserve your slot please follow: http://bit.ly/2TEeLfX
